New: Biosimilars strategies introduced.
Close
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
June 26, 2019 - FDA announced the discontinuation of ViiV Healthcare’s Rescriptor (delavirdine) 200 mg tablets.
Download PDF
Return to publications
